# Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

> **NCT02367651** · PHASE2 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Pazopanib 800 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02367651
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-06
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study cancelled: Withdrawn before enrollment of any participants
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367651, "Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02367651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*